Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-06
W
Wen Ling
Role not yet determined Is this you? Add your title
Also affiliated: Guangxi University (2024); Soochow University (2016); Soochow University (2014–2016); Longgang Central Hospital (2024); Institute for Musculoskeletal Health (2024); Winthrop Rockefeller Foundation (2019–2025); University of South China (2010)
17 h-index
66 pubs
1,582 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Wen Ling's research focuses on understanding and targeting the mechanisms of multiple myeloma, particularly its impact on bone. Ling has investigated the role of various factors in bone resorption and formation in the context of multiple myeloma, including antibody-based inhibition of DKK1, the effects of osteoblasts and mesenchymal stem cells, and the influence of proteasome inhibitors like bortezomib. Recent work has explored the ephrinB2/EphB4 axis in osteoprogenitors and its connection to myeloma bone disease, as well as the contribution of mitochondrial Sirt3 to age- or estrogen deficiency-related bone loss. Ling also studies Bruton's tyrosine kinase in myeloma cell migration and bone disease induction. Collaborations at the University of Arkansas for Medical Sciences include work with Shmuel Yaccoby, Nükhet Aykin‐Burns, Ha‐Neui Kim, and Kimberly J. Krager, with whom Ling shares multiple publications. Ling's scholarship metrics include an h-index of 17, 66 total publications, and 1,582 total citations.
Metrics
- h-index: 17
- Publications: 66
- Citations: 1,582
Selected Publications
-
Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma‐induced bone disease (2025)
-
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression (2023)
-
Growth and dormancy control of myeloma cells by mesenchymal stem cells (2023)
-
Hematopoietic cytoplasmic adaptor protein Hem1 promotes osteoclast fusion and bone resorption in mice (2022)
-
Ionizing Radiation Activates Mitochondrial Function in Osteoclasts and Causes Bone Loss in Young Adult Male Mice (2022)
-
Simulated Galactic Cosmic Rays Modify Mitochondrial Metabolism in Osteoclasts, Increase Osteoclastogenesis and Cause Trabecular Bone Loss in Mice (2021)
-
PHF19 inhibition as a therapeutic target in multiple myeloma (2021)
-
The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma (2019)
-
Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors (2018)
-
Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients (2016)
-
Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow (2015)
-
ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis (2014)
-
Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1 (2014)
-
Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells (2014)
-
GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts (2013)
Collaboration Network
Top Collaborators
Shmuel Yaccoby
University of Arkansas for Medical Sciences
48 shared publications
In database
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Showing 5 of 48 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
38 shared publications
In database
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 38 shared publications
Sharmin Khan
University of Arkansas for Medical Sciences
32 shared publications
In database
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 32 shared publications
Xin Li
University of Arkansas for Medical Sciences (US)
26 shared publications
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 26 shared publications
Frits van Rhee
Winthrop Rockefeller Foundation
18 shared publications
In database
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
- PHF19 inhibition as a therapeutic target in multiple myeloma
Showing 5 of 18 shared publications
John D. Shaughnessy
Winthrop Rockefeller Foundation
18 shared publications
In database
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone
Showing 5 of 18 shared publications
Angela Pennisi
University of Arkansas for Medical Sciences (US)
17 shared publications
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone
Showing 5 of 17 shared publications
Rakesh Bam
University of Arkansas for Medical Sciences (US)
17 shared publications
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow
- Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
- GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts
Showing 5 of 17 shared publications
Joshua Epstein
Winthrop Rockefeller Foundation (US)
16 shared publications
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
Showing 5 of 16 shared publications
Sathisha Upparahalli Venkateshaiah
University of Arkansas for Medical Sciences (US)
13 shared publications
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
- Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
- GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts
- Stearoyl CoA Desaturase 1 (SCD1) Is Upregulated in Rapidly Growing Myeloma Cells and Is Required for Cell Proliferation,
Showing 5 of 13 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
9 shared publications
In database
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- PTH and Bortezomib Suppress Growth of Primary Human Myeloma through Increased Bone Formation In Vivo.
- PHF19 inhibition as a therapeutic target in multiple myeloma
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
Showing 5 of 9 shared publications
Randal S. Shelton
Winthrop Rockefeller Foundation
8 shared publications
In database
- PHF19 inhibition as a therapeutic target in multiple myeloma
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro
- Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1
- Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis
Showing 5 of 8 shared publications
Rinku Saha
University of Arkansas for Medical Sciences (US)
8 shared publications
- PTH and Bortezomib Suppress Growth of Primary Human Myeloma through Increased Bone Formation In Vivo.
- Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma.
- Myeloma Cells Cultivate Megakaryocytes To Promote Lytic Bone Disease.
- Anti-Myeloma Response to Bortezomib Is Associated with Increased Osteoblast Activity and Bone Formation in Primary Myelomatous SCID-rab Mice.
- Atacicept (TACI-Ig) Inhibits Growth of TACIhigh Primary Myeloma Cells in SCID-Hu Mice.
Showing 5 of 8 shared publications
Guido Tricot
University of Arkansas for Medical Sciences
7 shared publications
In database
- PTH and Bortezomib Suppress Growth of Primary Human Myeloma through Increased Bone Formation In Vivo.
- Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma.
- Myeloma Cells Cultivate Megakaryocytes To Promote Lytic Bone Disease.
- Anti-Myeloma Response to Bortezomib Is Associated with Increased Osteoblast Activity and Bone Formation in Primary Myelomatous SCID-rab Mice.
- Atacicept (TACI-Ig) Inhibits Growth of TACIhigh Primary Myeloma Cells in SCID-Hu Mice.
Showing 5 of 7 shared publications
Sadie Johnson
Winthrop Rockefeller Foundation (US)
6 shared publications
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Inducible Heme Oxygenase 1 (HMOX1) Promotes Osteoblastogenesis, and Inhibits Osteoclastogenesis and Myeloma-Induced Bone Disease
- ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis
- Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Sharmin Khan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Hayley M. Sabol
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Aric Anloague
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Olivia Reyes‐Castro
University of Arkansas for Medical Sciences
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Mesenchymal stem cell research
Jesús Delgado‐Calle
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Disease Mechanisms Research
Cody Ashby
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Cells and Metastasis
Disease Mechanisms Research